UK Rejects Rx-To-OTC Switch Of Overactive Bladder Treatment
Executive Summary
Maxwellia’s application to switch to non-prescription status in the UK Aquiette (oxybutynin hydrochloride) for the treatment of overactive bladder has been rejected by MHRA following a public consultation.
You may also be interested in...
Nestlé Partner Valbiotis Hails Trial Results For Prediabetes Supplement
Valbiotis and Nestlé Health Science plan to launch in 2024 a dietary supplement targeted at sufferers of prediabetes and type-2 diabetes following positive results from a recent study which showed the product's efficacy on key markers of glucose metabolism.
Pierre Fabre Takes Stake In French Women's Health Start-Up
France's Pierre Fabre is enhancing its presence in the women's health market by taking a stake in dietary supplements and cosmetics firm MiYé.
Over A Quarter Of EU Consumers Increase Supplement Intake But Financial Pressures Take Toll
Research from Stada shows that while a quarter of European consumers increased their dietary supplement intake compared to last year, one in five have cut back spending on such products. These are among the findings of the Stada Health Report 2023 which asked 32,000 people more than 30 questions covering topics such as health prevention and satisfaction with national healthcare systems.